Since its introduction, the use of cetuximab in the treatment of head and neck squamous cell
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …

6001 Objective: Phase I study to determine the maximum tolerated dose (MTD) of 5-FU in
the Docetaxel/Cisplatin/5-Fluorouracil (TPF) regimen (Posner et al, NEJM 2007) when …

PURPOSE: To describe the clinical results and tolerance of the combined treatment with
radiotherapy and cetuximab for locally advanced head and neck cancer. PATIENTS AND …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

15502 Background: Previous studies with cetuximab in SCCHN demonstrate to be clinically
beneficial. In the present study we wished to evaluate the efficacy and safety of a …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

BACKGROUND We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …

Cetuximab is typically administered on a weekly schedule for patients with recurrent or
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …